Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a novel phospholipid ether PLE platform technology as a targeted delivery and retention vehicle, Cellectar s compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to find, treat and follow malignancies in a highly selective way. I CLR is a small molecule, broad spectrum, cancer targeted PET imaging agent. A Phase II trial evaluating I CLR in glioblastoma is expected to be completed in . Additionally multiple, investigator sponsored Phase I/II clinical trials are ongoing across solid tumor indications. I CLR is a small molecule, broad spectrum, cancer targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Data from a Phase Ib dose escalation trial of I CLR in patients with advanced solid tumors is anticipated in the first quarter of . CLR is a preclinical, cancer targeted, non radioactive optical imaging agent for intraoperative tumor margin illumination and non invasive tumor imaging. For additional information please visit www.cellectar.com
Quote | Cellectar Biosciences Inc. (NASDAQ:CLRB)
Last: | $1.835 |
---|---|
Change Percent: | -0.01% |
Open: | $1.7601 |
Close: | $1.835 |
High: | $1.84 |
Low: | $1.7601 |
Volume: | 14,009 |
Last Trade Date Time: | 06/09/2023 03:00:00 am |
News | Cellectar Biosciences Inc. (NASDAQ:CLRB)
2023-05-04 10:10:06 ET Cellectar Biosciences press release ( NASDAQ: CLRB ): Q1 GAAP EPS of -$0.76. As of March 31, 2023, the company had cash and cash equivalents of $12.7 million, compared to $19.9 million as of December 31, 2023. For further details see: ...
FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the first quarter ended...
Message Board Posts | Cellectar Biosciences Inc. (NASDAQ:CLRB)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CLRB News Article - Cellectar Reports Financial Results for First Quarter 2023 and Pro | whytestocks | investorshangout | 05/04/2023 12:55:45 PM |
whytestocks: $CLRB News Article - Cellectar Biosciences Reports Complete Response in a Relapsed/Refr | whytestocks | investorshangout | 02/28/2023 4:40:48 PM |
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Source:Edgar (US | abracky | investorshub | 12/12/2022 5:44:16 AM |
Look at $PSTV - All the due diligence | The Ultimate Choice | investorshub | 09/06/2022 1:47:38 PM |
whytestocks: $CLRB News Article - Cellectar Reports Financial Results for Second Quarter 2022 | whytestocks | investorshangout | 08/05/2022 5:01:10 PM |
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
News, Short Squeeze, Breakout and More Instantly...